<DOC>
	<DOC>NCT00185224</DOC>
	<brief_summary>The purpose of this study is to confirm the safety of SH T00658ID with regard to plasma lipids, hemostatic variables, and carbohydrate metabolism. In addition, the pharmacokinetic parameter following the long term administration of SH T00658ID will be assessed.</brief_summary>
	<brief_title>Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral, Sequential</mesh_term>
	<criteria>Healthy female volunteers between 18 and 50 years requiring contraception Pregnancy or lactation Any conditions that might interfere with the outcome as well as all contraindications for OC use</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>